FB1001 / 4B Technologies - LARVOL DELTA

Preclinical Findings of a Potent TrkB Agonistic Antibody in Attenuating Optic Nerve Degeneration (ARVO 2026) - "Conclusions FB1001-mediated TrkB activation protects RGCs and restores retinal structure. FB1001 shows potential as a promising clinical therapeutic candidate for optic nerve injury diseases represented by glaucoma."

Preclinical • Glaucoma • Ophthalmology • NGFR • NTRK2

Clinical Study of FB1001 in Patients (clinicaltrials.gov) - P1 | N=59 | Not yet recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

New P1 trial • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain